|
| |
Progenics PharmaceuticalsProgenics Pharmaceuticals, Inc., of Tarrytown, NY, is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward gastroenterology as well as the treatment of HIV infection and cancer. The Company has four product candidates in clinical development and several others in preclinical development. The Company, in collaboration with Wyeth, is developing methylnaltrexone for the treatment of opioid-induced side effects, including constipation and post-operative ileus. In the area of HIV infection, the Company is developing the viral-entry inhibitor, PRO 140, a humanized monoclonal antibody targeting the HIV coreceptor CCR5. In addition, the Company is conducting research on ProVax, a novel prophylactic HIV vaccine. The Company is developing in vivo immunotherapies for prostate cancer, including a human monoclonal antibody-drug conjugate directed against prostate-specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells.
Progenics is also developing vaccines designed to stimulate an immune response to PSMA, and has a recombinant PSMA vaccine in phase 1 clinical testing. The Company is also developing a cancer vaccine, GMK, in phase 3 clinical trials for the treatment of malignant melanoma.
| Contact Details: |
| 777 Old Saw Mill River Road |
| Tarrytown |
| New York |
| 10591 |
| United States of America |
| Tel: | 914-789-2800 |
| Fax: | 914-789-2817 |
| Email: | info@progenics.com |
| WWW: | www.progenics.com/
|
|
Loading...
|
Recent Publications by Progenics Pharmaceuticals: |  |
Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1.
SOSIP gp140 trimers represent a soluble, stabilized, proteolytically... | 11th September, 2009
| Progenics Pharmaceuticals, Inc., Tarrytown, NY 10591, United States.
| Vaccine. 2009 Aug 13;27(37):5120-32. Epub 2009 Jun 28.
DOI Direct Link |
CCR5 monoclonal antibodies for HIV-1 therapy.
PURPOSE OF REVIEW: To summarize emerging clinical and preclinical data... | 13th May, 2009
| Progenics Pharmaceuticals Inc, Tarrytown, NY 10591, USA.
| Curr Opin HIV AIDS. 2009 Mar;4(2):104-11.
DOI Direct Link |
A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses.
PURPOSE: Prostate-specific membrane antigen (PSMA) is an attractive target... | 7th September, 2007
| Progenics Pharmaceuticals, Inc., Tarrytown, New York 10591, USA.
| Clin Cancer Res. 2007 Jul 1;13(13):3999-4008.
DOI Direct Link |
Purified, proteolytically mature HIV type 1 SOSIP gp140 envelope trimers.
HIV type 1 (HIV-1) envelope is a noncovalent trimer of gp120-gp41... | 29th August, 2007
| Progenics Pharmaceuticals, Inc., Tarrytown, New York 10591, USA.
| AIDS Res Hum Retroviruses. 2007 Jun;23(6):817-28.
DOI Direct Link |
Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.
The chemokine receptor CCR5 provides a portal of entry for human... | 9th December, 2006
| Progenics Pharmaceuticals, Inc, Tarrytown, NY 10591, USA.
| Antimicrob Agents Chemother. 2006 Oct;50(10):3289-96.
DOI Direct Link |
→View more Progenics Pharmaceuticals research publications. |
Press Releases on Progenics Pharmaceuticals:
|
 |
| Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment |
26th October, 2009 |
Reportlinker |
-- A focus on "engineered" antibodies
Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment reviews the broad drug development effort that is focused on bringing
|
| New Report Just Published: World Prostate Cancer Therapeutics Market Report |
7th July, 2009 |
Reportlinker |
NEW YORK, July 7 /PRNewswire/ -- Reportlinker.com just added a new market research report to its catalogue.
World Prostate Cancer Therapeutics Market
http://www.reportlinker.com/p0119471/World
|
| Savient Announces Appointment of David Gionco as Chief Financial Officer |
12th February, 2009 |
Savient Pharmaceuticals, Inc. |
EAST BRUNSWICK, N.J., Feb. 12 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced the appointment of David G. Gionco to the position of Vice President, Chief
|
| The Board of International Biotechnology Trust Plc (“IBT”) today
|
1st May, 2005 |
International Biotechnology Trust |
The Board of International
Biotechnology Trust Plc (“IBT”) today announces its unaudited Annual Results for
the twelve months ended 31 August 2005
Summary
• Net asset value per share rose
|
| New Report from PharmaPlus: HIV Pipelines & Deals |
1st December, 2003 |
Pharmaplus |
New Report from PharmaPlus: HIV Pipelines & Deals
At the end
of November 2003 the joint United Nations Program on HIV/AIDS and the World
Health Organization presented
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 645 times since April 2007, the link to the organisation's website has been followed 101 times Recent Search Terms used to find this page: Progenics Pharmaceuticals Inc main markets | progenics pharmaceutical in az | progenic pro 140 | progenics pipeline | PSMA progenics patent | progenic PSMA patent rights | t lrunis 6710173 | progenics | pgnx | progenics | . Search for more companies in Tarrytown Search for more companies in New York This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Progenics Pharmaceuticals |
